Pasithea reports prolonged stable disease in PAS-004 cancer trial
Pasithea Therapeutics (KTTA) reported Phase 1 trial data for PAS-004, an oral MEK inhibitor, showing stable disease in advanced solid tumor patients. Four patients remained on treatment for over 300 days, with two over 500 days. No dose-limiting toxicities were observed. The data was presented at ESMO Congress 2026.
How this was made
The 30-second read
Why it matters
The absence of dose‑limiting toxicities and extended treatment durations suggest a favorable safety profile, potentially accelerating development milestones and attracting partnership interest.
Market read
First‑time disclosure of encouraging Phase 1 data for a micro‑cap oncology biotech, likely to move the stock.
What to watch
Small patient cohort and lack of comparative efficacy data could temper enthusiasm.
Background
Pasithea Therapeutics (NASDAQ:KTTA) presented Phase 1 results at the ESMO Congress 2026, highlighting safety and disease stability for its oral MEK inhibitor PAS-004.
Ticker impact
Pasithea Therapeutics disclosed updated Phase 1 data for PAS-004, showing prolonged stable disease and no dose‑limiting toxicities in 37 patients.
likely upward pressure as investors price in encouraging safety profile and durability of response.
Phase 1 data with no DLTs and long‑term treatment durations are rare for a micro‑cap biotech and can trigger speculative buying.
Market effects
May boost sentiment for MEK inhibitor and broader oncology pipeline stocks.
Limited to US biotech investors; no broader regional effect.
Modest, confined to specialty pharma and biotech community.
Counterpoint
Data are early‑stage; durability and efficacy remain unproven, risk of later‑stage failure persists.
Key entities
- companyPasithea Therapeutics Corp.
Biotech developing oral MEK inhibitor PAS-004.
- drugPAS-004
Oral MEK inhibitor being evaluated in advanced solid tumors.
